Abstract
Neuroblastoma, a primary tumor of the central nervous system that affects over 80% of cases in children under 5 years old, poses a significant challenge due to its rapid progression and resistance to conventional therapies such as surgical resection, radiotherapy, chemotherapy, and hormonal treatments. Telomerase, a crucial enzyme in maintaining the chromosomal ends called telomeres, has …